PartnershipIt seems that a sale of the company would be very discriminatory to shareholders with the SP being where it is but a partnership is probably the way to go. Knowing that management loves these public conversations, my opinion is that they really have demonstrated an incredibly limited capability to adhere value to the company. This valuation may be the lowest rung married to the worst case scenario in the hottest biotech market in history. The valuation is so pathetic that this conversation doesn't need to happen. TST needs a partnership to legitimize and validate it. Clearly it will not happen otherwise, short of an outright FDA approval. Partner MCNA without giving up your de risking dialogue and show some type of value to shareholders. Things here are so bad that people get excited moving from 1/18th the valuation of TST's P1 and P2 peer value to 1/10th. Would you be that over the moon selling your house for 1/10th your neighbor's while you live on 10 times the lot?